Efficacy and safety of cumaru syrup as complementary therapy in mild persistent asthma: a double-blind, randomized, placebo-controlled study

Abstract

Amburana cearensis is a medicinal plant known as "cumaru". It is used in Northeast Brazil in the treatment of respiratory diseases. This was a randomized, double-blind, placebo-controlled study, with the aim of evaluating the efficacy and safety of cumaru syrup as complementary therapy in mild persistent asthma. The study consisted of 3 phases, pre-treatment, treatment and post-treatment. The primary efficacy outcome was comparison of the changes reported by patients of the cumaru and placebo groups after treatment, using the "Asthma Quality of Life Questionnaire" (AQLQ). The secondary outcome was the effect of cumaru syrup on lung function based on spirometry. The results showed that in the cumaru group, the proportion of patients who had global improvement in asthma symptoms was significantly greater (61.90%, P=0.0009) than in the placebo group (9.52%). Only the spirometric parameters Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) showed significant intergroup differences in post-treatment (P<0.05). The hematological and serum chemistry tests performed in the pre-treatment and post-treatment showed no statistically significant differences (P>0.05). Adverse events were reported by 3 patients (14.29%) in the cumaru group and 3 patients (14.29%) in the placebo group. All adverse events were considered non-serious and mild.

Chamb (Justicia pectoralis) syrup for the treatment of cough and respiratory symptoms: A randomized clinical trial

“…There was a statistically significant improvement in asthma symptoms as measured by the "Asthma Quality of Life Questionnaire", and spirometric parameters (Carvalho et al, 2012).…”

Estudos De Plantas Para Tratamento Da Bronquite, Asma E Covid-19: Uma Revisão De Literatura

“…A adesão ao tratamento medicamentoso foi satisfatória, não havendo piora no controle da asma ou aumento em hospitalizações entre os usuários de plantas medicinais. Os autores Carvalho et al, (2012) mostraram que no grupo cumaru, a proporção de pacientes que tiveram melhora global dos sintomas de asma foi significativamente maior (61,90%, p=0,0009) do que no grupo placebo (9,52%). Apenas os parâmetros espiro métricos -Capacidade Vital Forçada (CVF) e Volume Expiratório Forçado em 1 segundo (VEF1) apresentaram diferenças significativas entre os grupos no pós-tratamento (p<0,05).…”